Avista Pharma Solutions has completed the acquisition of Solid Form Solutions located in Edinburgh, Scotland. Solid Form Solutions is a provider of solid state chemistry and crystallization development services for clients in the pharmaceutical industry. The addition of Solid Form Solutions expands Avista’s existing solid phase chemistry services and provides both companies’ customers access to a full suite of drug development services ranging from analytical development to active pharmaceutical ingredient (API) and drug product manufacturing.

“This acquisition is evidence of our ongoing commitment to provide our clients the most efficient path to success with their drug development and manufacturing projects,” said Patrick Walsh, chief executive officer, Avista Pharma. “Solid Form Solutions has a reputation of providing valuable early phase services that significantly reduce risk and improve speed later during the drug development process.”

Solid Form Solutions will continue operating in its Edinburgh facility, providing clients with services including salt screening and selection, co-crystal and polymorph screening, crystallization development, and other analytical testing and development.

“Solid Form Solutions has been built on deep scientific expertise and an intense focus on the needs of our clients, and those characteristics directly align with our colleagues at Avista Pharma,” said Stephen Watt, chief executive officer, Solid Form Solutions. “We are excited to be able to bring a broader array of drug development services to our clients while avoiding the time and costs associated with tech transfer to a third-party.”

The acquisition of Solid Form Solutions follows a year of significant investment in facilities and capacity expansion for Avista Pharma. During 2017, Avista Pharma announced the expansion of its analytical research and development capabilities in Durham, NC, its API and drug product manufacturing capacity in Longmont, CO, and its microbiology and sterility testing capabilities in Agawam, MA.